Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 8975 results

  1. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Magtrace/Sentimag MT599 (MIB263)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  13. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

    NICE guideline
    In development

  14. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

    In development Reference number: GID-TA11733 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development